Stockreport

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

Verve Therapeutics, Inc.  (VERV) 
PDF Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First p [Read more]